Screening for Anemia and Iron Deficiency in the Adult Portuguese Population by Robalo Nunes, António et al.
Research Article
Screening for Anemia and Iron Deficiency in the Adult
Portuguese Population
António Robalo Nunes ,1,2 João Mairos,1,3 Dialina Brilhante,1,4 Filipa Marques,1,5
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Anemia and iron deficiency (ID) can impair quality of life and socioeconomic development. We evaluated the prevalence of
anemia and ID in the adult Portuguese population in real-life contexts by gender, age, and pregnancy status. We performed a
cross-sectional screening in adult individuals in mainland Portugal from 2013 to 2017. Participants completed a survey about
demographics and signs or symptoms compatible with anemia, and ID and hemoglobin and ferritin concentrations were de-
termined by point-of-care tests. We estimated and compared prevalence ratios (PR) of anemia and ID using Poisson regression
with robust variance and the Wald chi-square test. We collected data from 11,030 individuals (26% men, 64% nonpregnant
women, and 10% pregnant women). We found anemia in 51.8% (95% CI 50.1–53.4%) of nonpregnant women in fertile age, 46.6%
(95% CI 44.7–48.6%) of nonpregnant women >51 years, 38.2% (95% CI 35.4–41.1%) of pregnant women, and 33.3% (95% CI
31.6–35.1%) of men. 'e prevalence of ID was 72.9% (95% CI 71.4–74.4%) in nonpregnant women in fertile age, 50.5% (95% CI
48.5–52.4%) in nonpregnant women >51 years, 94.8% (95% CI 93.3–96.0%) in pregnant women, and 28.9% (95% CI 27.3–30.6%)
in men. We found significant associations between the prevalence of anemia or ID and nonpregnant women (PR: 1.50, 95% CI
1.42–1.59 or PR: 2.21, 95% CI 2.09–2.35, respectively), manifestation of signs or symptoms (PR: 1.19, 95% CI 1.53–1.23 or PR: 1.22,
95% CI 1.18–1.26), pregnant women (PR: 0.74, 95% CI 0.68–0.80 or PR: 1.30, 95% CI 1.27–1.33), and nonpregnant women ≤51
years (PR: 1.11, 95% CI 1.06–1.17 or PR: 1.42, 95% CI 1.36–1.48). In conclusion, anemia and ID represent moderate to severe
public health problems, particularly among women in fertile age and in 3rd trimester, of pregnancy emphasizing the need to raise
the public and health professionals’ awareness of these problems and their prevention, diagnosis, and treatment.
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1. Introduction
Anemia, defined as a decreased hemoglobin concentration
[1], is a major global public health problem affecting about
one-quarter of the world’s population [2]. In Europe, the
World Health Organization (WHO) has estimated a prev-
alence of anemia of approximately 23% for children ≤5
years, 23% for nonpregnant women in fertile age, and 26%
for pregnant women in 2011 [3]. In Portugal, recent studies
have estimated a prevalence of anemia of 20% in the Por-
tuguese general population, particularly affecting women
(21%), pregnant women (54%), and adults aged ≥65 years
(21%) [4, 5].
Anemia may result from several causes, such as
micronutrient deficiencies (iron, folate, and vitamin B12),
genetic disorders, or other conditions that may induce iron
loss or decreased iron absorption (acute or chronic infection,
inflammatory bowel disease, chronic heart failure, chronic
kidney disease, neoplasm, and autoimmune disease) [3, 6, 7].
Iron deficiency (ID) is a major contributing factor of anemia
in developed countries, generally caused by an insufficient
dietary iron intake or by conditions causing hemorrhage or
decreased iron absorption [3, 6–8]. Approximately, 50% of
anemia cases can be explained by ID. However, this pro-
portion can vary among different local conditions and
population groups [3–5, 9–12]. ID is more likely to occur
when the iron requirements are increased, such as during
periods of rapid growth and increased erythropoiesis
(children and adolescents), additional requirements (preg-
nancy), or due to menstrual bleeding and insufficient dietary
iron intake (women in fertile age) [8, 11–13]. In contrast, the
elderly population is particularly susceptible to anemia of
chronic disease, which generally lacks a known underlying
cause [6, 10]. Anemia of chronic disease is commonly as-
sociated with several prevalent conditions in the elderly
population, such as chronic infections, inflammatory dis-
eases (heart failure, chronic kidney disease, and immune
diseases), and neoplasms [10]. Common causes of ID in the
elderly population include disorders and/or acute or chronic
hemorrhage through the gastrointestinal tract [8, 10].
Anemia and ID can have adverse health effects impairing
quality of life [14, 15] and socioeconomic development
[3, 16]. In children, ID anemia negatively affects motor and
cognitive development, and, in adults, it is associated with
fatigue, decreased physical performance, and lower pro-
ductivity [3, 8, 12]. During pregnancy, ID anemia has been
associated with low birth weight, premature delivery, and
increased risk of perinatal mortality [3, 12, 13]. In the elderly
population, anemia is associated with frailty, decreased
cognitive function, and a global increase in morbidity and
mortality [10]. ID, by itself, can have deleterious effects as the
use of iron supplementation to correct ID without anemia
has been associated with beneficial effects in women in fertile
age or pregnancy [8].
'e high prevalence and negative impact of anemia and
ID in high-risk population groups make these conditions
public health problems that must be taken into consider-
ation [3–5, 7, 10]. However, the relevance and best strategies
of screening and treating ID or ID anemia in different
populations are still unclear [6, 8]. On the one hand, ID is a
widespread problem in clinical practice, and several
guidelines for the diagnosis and treatment of anemia or ID
exist and vary between different medical specialties and
populations [6, 7]. On the other hand, to increase the
prevention or treatment of anemia and ID, additional
studies are needed to characterize the local etiology, prev-
alence, and most affected population groups [3, 17]. Finally,
epidemiological data on anemia and ID are sparse
[4, 5, 9, 11, 18]. 'erefore, we aimed to evaluate the prev-
alence of anemia and ID in different groups of the adult
Portuguese population stratified by age, gender, and in the
case of women, by pregnancy status. 'is study was con-
ducted in real-life contexts, in which the participants were
asked to complete a survey as well as screening tests for
anemia and ID. Additionally, we aimed to raise awareness
among the public, health professionals, and policy-makers
about the extent of anemia and ID problem in Portugal and
possible future interventions.
2. Materials and Methods
2.1. Study Design. 'is cross-sectional screening was pro-
moted by the AnemiaWorking Group Portugal—Associação
Portuguesa para o Estudo da Anemia—aiming to evaluate
the prevalence of anemia and ID in different demographic
groups of the adult Portuguese population. 'e screening
was performed using a convenience sampling in real-life
contexts, such as public locations and private entities fre-
quented by the general population. 'e screening was
carried out in several geographical locations in mainland
Portugal from January 2013 to December 2017. 'e study
was conducted by applying a survey as well as anemia and ID
screening blood tests to the participants, in which hemo-
globin and ferritin concentrations were determined by
point-of-care tests.
'e study received approval from the Portuguese Na-
tional Data Protection Committee (CNPD, Lisbon, Portu-
gal). All the participants voluntarily participated in this
study and provided their oral consent after clarification
about the scope of the screening.
2.2. Participants andProcedures. 'e study enrolled all adult
individuals (≥18 years old) that, after an invitation to par-
ticipate in the screening in several public locations, such as
public or private health institutions, pharmacies, shopping
centers, companies, and medical and healthcare congresses,
they showed availability and interest to participate.
'e participants were asked to answer a survey about
anemia and ID. 'e survey included questions about de-
mographic characteristics and the presence or absence of
signs or symptoms compatible with the presence of anemia
or ID. 'e last were collected using three categories: (1)
fatigue in daily activities; (2) bleed easily, headaches, and
dizziness; and (3) visible blood loss. If the participants
answered positively to at least one question of these cate-
gories, they were considered as having a sign or symptom
compatible with the presence of anemia or ID (see Figure S1
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in the Supplementary Material for analysis of the survey’s
form).
Hemoglobin and ferritin concentrations were deter-
mined by point-of-care testing devices using capillary
puncture performed by the research team. 'is team con-
sisted of trained individuals in the survey methodology and
the execution of point-of-care tests by capillary puncture,
mostly health professionals (nurses and lab technicians).
Hemoglobin and ferritin concentrations were determined
using Cera-Chek Hb Plus (Ceragem Medisys, Chungnam,
South Korea) and Vedalab Easy Reader (Vedalab, Alençon,
France), respectively.
2.3. Definition of Anemia and Iron Deficiency. Anemia was
defined as hemoglobin concentration <12.0 g/dL for non-
pregnant women, <13.0 g/dL for men, <11.0 g/dL for
pregnant women in the 1st or 3rd trimester, and <10.5 g/dL
for pregnant women in the 2nd trimester, in accordance with
the WHO [1] and the Portuguese Directorate-General for
Health (DGS, Lisbon, Portugal) [19] guidelines.
ID was classified according to the ferritin concentration,
which is positively correlated with the magnitude of the total
body iron stores in the absence of inflammation [20]. Several
ferritin cutoffs have been proposed in the literature for the
diagnosis of ID in the general population, and there are no
consensus criteria [7]. Ferritin concentrations <15 ng/mL
are indicative of iron stores depletion in both genders [20].
In the presence of factors that affect ferritin levels such as
age, inflammation, infection, or pregnancy, ferritin con-
centrations <30 ng/mL are also indicative of iron stores
depletion [20]. 'e DGS indicates serum ferritin concen-
trations of 30 to 340 ng/mL as normal reference ranges in the
general adult population and recommends that pregnant
women should initiate oral iron therapy if their serum
ferritin concentration is <70 ng/mL [19]. 'erefore, in this
study, ID was defined as a ferritin concentration <30 ng/mL
in men and nonpregnant women and <70 ng/mL in preg-
nant women, regardless of the pregnancy trimester [19].
2.4. Statistical Analysis. A convenience sampling of the
general adult population was conducted at several public and
private locations for five consecutive years in mainland
Portugal. A sample size calculation was not performed.
Participants were excluded from the analysis if they had
missing data regarding any of the following variables: age,
gender, hemoglobin concentration, ferritin concentration,
or pregnancy trimester.
Data from the sample population were stratified by
gender, age, and presence or absence of signs or symptoms
of anemia or ID, to estimate and compare the prevalence of
anemia or ID between groups. Female participants were
stratified into nonpregnant women (age ≥18 years) and
pregnant women in the 1st, 2nd, or 3rd trimester of ges-
tation. Nonpregnant women in fertile age (18–44 years) and
pregnant women were matched by the following age groups:
18–26, 27–35, and 36–44 years. To evaluate the relationship
of menopause with the prevalence of anemia or ID, non-
pregnant women were further stratified into the age groups
≤51 years and >51 years. Because the scope of the screening
did not include the report of a clinical diagnosis of men-
opause (i.e., 12 consecutive months of amenorrhea without
any other obvious pathological or physiological cause) and
because menopause is an event that occurs at a median age of
51 years [21–24], we have used this cutoff to stratify women
into pre- and postmenopause.
'e normality of the data was assessed using the Kol-
mogorov–Smirnov test. Continuous variables were pre-
sented as mean (standard deviation), median
(minimum–maximum), or median (1st quartile–3rd quar-
tile), as applicable. Categorical variables were expressed as
number and percentage. Each prevalence estimate of anemia
or ID was expressed as a percentage with the respective 95%
Clopper–Pearson confidence interval (CI). To assess the
relationship between anemia or ID and different population
groups or the presence of signs or symptoms of anemia or
ID, crude prevalence ratios (PR) with their corresponding
95% CI were estimated using Poisson regression with robust
variance. Pairwise comparisons of each PR versus the ref-
erence group were performed using the Wald chi-square
test.
Statistical significance was reported for p value<0.05. All
data analyses were carried out using SPSS for Windows,
version 25.0 (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Sample Characterization. During the study period, be-
tween 2013 and 2017, we collected data from 11,384 par-
ticipants that resulted from 135 events of anemia and ID
screenings. We excluded 354 cases from the initial screening
sample, corresponding to participants with age <18 years
(n� 86) or participants’ records that presented missing data
(n� 268).
We included 11,030 adult participants with ages between
18 and 99 years, 25.8% (n� 2845) of men, 64.0% (n� 7060)
of nonpregnant women, and 10.2% (n� 1125) of pregnant
women.'eir mean age was 40.90 (16.86), 45.94 (16.02), and
30.89 (4.84), respectively. Table 1 shows the summary sta-
tistics for demographic characteristics and hemoglobin and
ferritin concentrations of the study participants.
3.2. Prevalence of Anemia and Iron Deficiency
3.2.1. Health Institutions versus Other Public Locations.
'e prevalence and prevalence ratios of anemia and ID by
the type of location of the participant are presented in
Supplementary Table S2 (Supplementary Materials). We
estimated an anemia prevalence of 56.7% (95% CI
55.2–58.1%) in participants from health institutions and
35.6% (95% CI 34.5–36.8%) in participants from other
public locations. Furthermore, we found a significant as-
sociation between having anemia and the type of institution
of the participant. Compared with participants from other
public locations, participants from health institutions were
associated with a PR of anemia of 1.59 (95% CI 1.50–1.68,
p< 0.001).
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Regarding ID, we estimated a prevalence of 59.6% (95%
CI 58.2–61.0%) in participants from health institutions and
57.0% (95% CI 55.8–58.3%) in participants from other
public locations. No significant association was found be-
tween the prevalence of ID and the type of institution of the
participant.
3.2.2. Men versus Nonpregnant Women. 'e prevalence of
anemia and ID by gender is presented in Figure 1. We
estimated an anemia prevalence of 33.3% (95% CI
31.6–35.1%) in men and 50.0% (95% CI 48.9–51.2%) in
nonpregnant women. Furthermore, we found a significant
association between having anemia and gender. Compared
with men, nonpregnant women were associated with a PR of
anemia of 1.50 (95% CI 1.42–1.59, p< 0.001).
Regarding ID, we estimated a prevalence of 64.1% (95%
CI 62.9–65.2%) in nonpregnant women and 28.9% (95% CI
27.3–30.6%) in men. Similar to anemia, nonpregnant
women were associated with a significantly higher preva-
lence of ID compared with men (PR: 2.21, 95% CI 2.09–2.35;
p< 0.001).
3.2.3. Presence of Signs or Symptoms of Anemia or Iron
Deficiency. Figure 2 shows the prevalence of signs or
symptoms compatible with anemia or ID by the anemia or
ID status in the study sample. Most of the participants with
anemia (63.8%, 95% CI 62.4–65.1%) or with ID (62.9%, 95%
CI 61.7–64.1%) presented signs or symptoms compatible
with these conditions. Furthermore, we found a statistically
significant association between the presence of signs or
symptoms and the presence of anemia or ID. Participants
with anemia were associated with a PR of 1.19 (95% CI
1.15–1.23, p< 0.001) compared with those without anemia.
Similarly, participants with ID had a statistically higher
prevalence of signs or symptoms compared with participants
without ID (PR: 1.22, 95% CI 1.18–1.26; p< 0.001).
3.2.4. Nonpregnant Women versus Pregnant Women.
Table 2 shows the prevalence and the PR of anemia in
nonpregnant women in fertile age and pregnant women
stratified by age and pregnancy trimester. Overall, we found
a prevalence of anemia of 51.8% (95% CI 50.1–53.4%) in
nonpregnant women in fertile age and 38.2% (95% CI
35.4–41.1%) in pregnant women. Furthermore, we estimated
a significant association between anemia and pregnancy
status, in which pregnant women had a 0.74-fold lower
prevalence of anemia compared to nonpregnant women in
fertile age (Table 2). 'is significant lower PR of anemia in
pregnant women versus nonpregnant women in fertile age
was observed in all age groups (18–26 years, 27–35 years, and
36–44 years).
When analyzing pregnant women by their pregnancy
trimester, we recorded that almost half of the pregnant
women in the 3rd trimester (48.6%, 95% CI 43.9–53.3%) had
anemia compared to less than one-third of the pregnant
women in the 1st (26.8%, 95% CI 14.2–42.9%) and 2nd
trimesters (31.6%, 95% CI 28.0–35.4%). What stands out in
Table 2 is the high prevalence of anemia in 3rd trimester
pregnant women, which was not significantly different
compared to nonpregnant women in fertile age in all groups.
Conversely, pregnant women in the 1st and 2nd trimesters
had a significant 48% and 39% decrease, respectively, in the
overall prevalence of anemia compared to nonpregnant
women in fertile age (Table 2).
Table 3 shows the prevalence and the PR of ID in
nonpregnant women in fertile age (ferritin <30 ng/mL) and
in pregnant women (ferritin <70 ng/mL) stratified by age
and pregnancy trimester. In the total group, the prevalence
Table 1: Summary of the demographic characteristics and concentrations of hemoglobin and ferritin of the study participants.
Group
Participants, N� 11,030
n Age, mean (SD) (years) Hb, mean (SD) (g/dL) Ferritin, median (Q1–Q3) (ng/mL)
Men 2845 40.90 (16.86) 13.62 (1.65) 50.82 (26.60–86.80)
Nonpregnant women
Total 7060 45.94 (16.02) 12.01 (1.54) 21.28 (9.00–40.46)
≤51 years 4525 36.02 (9.04) 11.94 (1.53) 17.78 (9.00–33.46)
>51 years 2535 63.66 (8.91) 12.14 (1.55) 29.96 (14.28–56.00)
Pregnant women
Total 1125 30.89 (4.84) 11.15 (1.41) 17.38 (9.00–30.94)
1st trimester 41 30.44 (5.26) 11.74 (1.40) 29.60 (9.00–45.49)
2nd trimester 633 30.67 (4.75) 11.16 (1.39) 20.44 (9.00–36.12)
3rd trimester 451 31.24 (4.90) 11.09 (1.44) 10.80 (9.00–23.94)
18–26 years 203 23.90 (2.08) 11.23 (1.51) 16.80 (9.00–29.12)
27–35 years 723 30.87 (2.51) 11.13 (1.40) 17.78 (9.00–31.78)
36–44 years 199 38.07 (1.89) 11.14 (1.36) 16.94 (9.00–30.94)
Nonpregnant women in fertile agea
Total 3500 32.54 (7.14) 11.96 (1.52) 16.94 (9.00–32.20)
18–26 years 870 23.24 (2.37) 11.95 (1.53) 14.10 (9.00–27.44)
27–35 years 1285 30.91 (2.61) 12.01 (1.47) 17.78 (9.00–32.62)
36–44 years 1345 40.13 (2.53) 11.92 (1.56) 17.78 (9.00–35.28)
Hb, hemoglobin;N, total number of participants; n, number of participants per group;Q1, 1st quartile;Q3, 3rd quartile; SD, standard deviation. aSubgroups of






















Figure 1: Prevalence of anemia and iron deficiency in men (white bars, n� 2845) and nonpregnant women (grey bars, n� 7060). Error bars



























































Figure 2: Prevalence of the presence of signs or symptoms of anemia or iron deficiency in (a) participants without anemia (n� 6120) or with
anemia (n� 4910) and (b) participants without iron deficiency (n� 4619) or with iron deficiency (n� 6411). Error bars indicate 95%
confidence intervals. ID, iron deficiency.
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of ID was 72.9% (95% CI 71.4–74.4%) in nonpregnant
women in fertile age and 94.8% (95% CI 93.3–96.0%) in
pregnant women. 'e most striking result to emerge from
the data is that pregnant women in the 2nd and 3rd tri-
mesters presented a prevalence of ID above 90%, regardless
of the age group.'e 3rd trimester pregnant women showed
the highest prevalence, ranging from 97.8% (95% CI
92.1–99.7%) in the 36–44-year group to 98.7% (95% CI
92.9–100) in the 18–26-year group.
Moreover, we found that pregnant women had a
prevalence of ID that was 1.30-fold higher than nonpregnant
women in fertile age in the total group (Table 3), suggesting
that ID was associated with the pregnancy status. We found
the highest PR for ID in 3rd trimester pregnant women,
compared to nonpregnant women in fertile age in the total
group (PR: 1.34, 95% CI 1.31–1.38; p< 0.001) and the 36–44-
year group (PR: 1.40, 95% CI 1.33–1.46; p< 0.001).
We also aimed to compare the prevalence of anemia or
ID between nonpregnant women in pre- and post-
menopause, based on the stratification of nonpregnant
women into the age groups ≤51 and >51 years. Figure 3
shows the prevalence of anemia and ID in these groups of
nonpregnant women.
We found a prevalence of anemia of 51.9% (95% CI
50.5–53.4%) in nonpregnant women ≤51 years and 46.6%
(95% CI 44.7–48.6%) in nonpregnant women >51 years.
Moreover, we found a significant association between these
age groups and the prevalence of anemia, which showed an
11% increase in nonpregnant women ≤51 years compared to
nonpregnant women >51 years (PR: 1.11, 95% CI 1.06–1.17;
p< 0.001).
We found similar results for ID. 'e prevalence of ID
was 71.7% (95% CI 70.3–73.0%) in nonpregnant women ≤51
years and 50.5% (95% CI 48.5–52.4%) in nonpregnant
women >51 years. We also found a significant association
between these age groups and prevalence of ID, which
showed a 42% increase in nonpregnant women ≤51 years
compared to nonpregnant women >51 years (PR: 1.42, 95%
CI 1.36–1.48; p< 0.001). 'e results and discussion may be
presented separately, or in one combined section, and may
optionally be divided into headed subsections.
4. Discussion
In this study, we conducted a large-scale screening
(n� 11030) for anemia and ID in the adult Portuguese
population between 2013 and 2017. 'is study was per-
formed in real-life contexts both within and outside the
clinical setting, allowing not only to obtain more prevalence
data on population groups generally less accessible outside
the clinical context, such as adult men, but also on high-risk
groups within the population, such as pregnant women.
'erefore, we analyzed the extent of anemia and ID, which
has been poorly studied in different population groups, to
increase the amount of epidemiological data available for
healthcare planning.
Table 2: Prevalence and prevalence ratio of anemia in nonpregnant and pregnant women stratified by age group and pregnancy trimester.
Group
Anemia
N n Prevalence, % (95% CI) PR (95% CI)
Total
NPW in fertile agea 3500 1812 51.8 (50.1–53.4) 1 (reference)
Pregnant women 1125 430 38.2 (35.4–41.1) 0.74 (0.68–0.80)∗∗∗
1st trimester 41 11 26.8 (14.2–42.9) 0.52 (0.31–0.86)∗
2nd trimester 633 200 31.6 (28.0–35.4) 0.61 (0.54–0.69)∗∗∗
3rd trimester 451 219 48.6 (43.9–53.3) 0.94 (0.85–1.04)
18–26 years
NPW in fertile agea 870 445 51.1 (47.8–54.5) 1 (reference)
Pregnant women 203 74 36.5 (29.8–43.5) 0.71 (0.59–0.86)∗∗
1st trimester 10 0 0.0 (0.0–30.8) -b
2nd trimester 117 33 28.2 (20.3–37.3) 0.55 (0.41–0.74)∗∗∗
3rd trimester 76 41 53.9 (42.1–65.5) 1.06 (0.85–1.31)
27–35 years
NPW in fertile agea 1285 634 49.3 (46.6–52.1) 1 (reference)
Pregnant women 723 281 38.9 (35.3–42.5) 0.79 (0.71–0.88)∗∗∗
1st trimester 23 10 43.5 (23.2–65.5) 0.88 (0.55–1.41)
2nd trimester 414 133 32.1 (27.6–36.9) 0.65 (0.56–0.76)∗∗∗
3rd trimester 286 138 48.3 (42.3–54.2) 0.98 (0.86–1.12)
36–44 years
NPW in fertile agea 1345 733 54.5 (51.8–57.2) 1 (reference)
Pregnant women 199 75 37.7 (30.9–44.8) 0.69 (0.58–0.83)∗∗∗
1st trimester 8 1 12.5 (0.3–52.7) 0.23 (0.04–1.44)
2nd trimester 102 34 33.3 (24.3–43.4) 0.61 (0.46–0.81)∗∗
3rd trimester 89 40 44.9 (34.4–55.3) 0.83 (0.65–1.04)
CI, confidence interval;N, total number of participants; n, number of participants with anemia; NPW, nonpregnant women; PR, prevalence ratio. aSubgroups
of nonpregnant women matched to the same age groups of the pregnant women. bPoisson regression was not performed because the prevalence equals zero.
∗p value <0.05, ∗∗p value <0.01, ∗∗∗p value <0.001; Wald chi-square test.
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We found anemia to be highly prevalent in the screened
adult general population: 33% in men, 38% in pregnant
women, 47% in nonpregnant women >51 years, and 52% in
both in nonpregnant women in fertile age (18–44 years) and
nonpregnant women <51 years. 'ese prevalence estimates
of anemia are above the ones previously reported in the
WHO [3] and EMPIRE [4, 5] studies on the Portuguese
general population. 'e prevalence of anemia was partic-
ularly high in nonpregnant women in fertile age, exceeding
the estimated value for pregnant women, therefore con-
trasting with the estimates from WHO (19% nonpregnant
versus 26% pregnant) [3] and the EMPIRE study (21%
nonpregnant versus 54% pregnant) [4]. 'ese differences
may be explained not only by different study designs but also
by differences in the demographic characteristics and the
sample size used to estimate the prevalence of anemia. In the
present study, we analyzed 3500 nonpregnant women in
fertile age and 1125 pregnant women, whereas the EMPIRE
study [4] analyzed 2245 and 59, respectively. Nevertheless,
our findings are consistent with that of the EMPIRE study
[4] because the reported prevalence estimates make anemia a
moderate (20–39%) to severe (≥40%) public health problem
in the population groups at higher risk, namely, the women
in fertile age both nonpregnant or pregnant [2, 16].
In this study, we have reported a higher prevalence of
cases with signs or symptoms compatible with anemia or ID
in participants with anemia or with ID. Although the




N n Prevalence, % (95% CI) PR (95% CI)
Total
NPW in fertile agea 3500 2553 72.9 (71.4–74.4) 1 (reference)
Pregnant women 1125 1066 94.8 (93.3–96.0) 1.30 (1.27–1.33)∗∗∗
1st trimester 41 36 87.8 (73.8–95.9) 1.20 (1.07–1.35)∗∗
2nd trimester 633 588 92.9 (90.6–94.8) 1.27 (1.24–1.31)∗∗∗
3rd trimester 451 442 98.0 (96.2–99.1) 1.34 (1.31–1.38)∗∗∗
18–26 years 3
NPW in fertile agea 870 679 78.0 (75.1–80.8) 1 (reference)
Pregnant women 203 195 96.1 (92.4–98.3) 1.23 (1.18–1.29)∗∗∗
1st trimester 10 10 100 (69.2–100) 1.28 (1.24–1.33)∗∗∗
2nd trimester 117 110 94.0 (88.1–97.6) 1.21(1.14–1.28)∗∗∗
3rd trimester 76 75 98.7 (92.9–100) 1.26 (1.21–1.32)∗∗∗
27–35 years
NPW in fertile agea 1285 932 72.5 (70.0–75.0) 1 (reference)
Pregnant women 723 682 94.3 (92.4–95.9) 1.30 (1.25–1.35)∗∗∗
1st trimester 23 19 82.6 (61.2–95.0) 1.14 (0.94–1.38)
2nd trimester 414 383 92.5 (89.5–94.9) 1.28 (1.22–1.33)∗∗∗
3rd trimester 286 280 97.9 (95.5–99.2) 1.35 (1.30–1.40)∗∗∗
36–44 years
NPW in fertile agea 1345 942 70.0 (67.5–72.5) 1 (reference)
Pregnant women 199 189 95.0 (91.0–97.6) 1.36 (1.30–1.42)∗∗∗
1st trimester 8 7 87.5 (47.3–99.7) 1.25 (0.96–1.63)
2nd trimester 102 95 93.1 (86.4–97.2) 1.33 (1.25–1.42)∗∗∗
3rd trimester 89 87 97.8 (92.1–99.7) 1.40 (1.33–1.46)∗∗∗
CI; confidence interval; ID, iron deficiency; N, total number of participants; n, number of participants with iron deficiency; NPW, nonpregnant women; PR,
prevalence ratio. aSubgroups of nonpregnant women matched to the same age groups of the pregnant women. ∗∗p value <0.01, ∗∗∗p value <0.001; Wald chi-



















NPW ≤ 51 years 
NPW > 51 years
Figure 3: Prevalence of anemia and iron deficiency in nonpregnant
women aged ≤51 years (grey bars, n� 4525) and >51 years (white
bars, n� 2535). Error bars indicate 95% confidence intervals. ID,
iron deficiency; NPW, nonpregnant women.
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presence of anemia or ID has shown a significant association
with the manifestation of compatible signs or symptoms,
these are generally nonspecific and can result from several
etiologies and comorbidities [6].
'e ID was also found to be highly prevalent in the
screened adult general population. Adult men showed the
lowest prevalence of ID (29%), whereas nonpregnant
women >51 years, nonpregnant women in fertile age, and
pregnant women presented a prevalence of ID of 51%, 72%,
and 95%, respectively. Similar to anemia, the prevalence
estimates for ID are above those previously reported by the
EMPIRE study [4], mainly for nonpregnant women in fertile
age (38%) and pregnant women (63%). It should be high-
lighted that, despite being in line with the EMPIRE study,
our results support a higher prevalence of both anemia and
ID, which could be explained by the different study designs,
as already mentioned, and also by the increased number of
women participants in our study, including nonpregnant
women of fertile age (n� 3500) and ≤51 years (n� 4525), as
well as pregnant women (n� 1125).
We found significant associations between gender and
the prevalence of anemia and ID when we compared men to
nonpregnant women. When analyzing the proportion of
cases with ID and anemia, we observed a prevalence of ID of
29% and a prevalence of anemia of 33% in men, and a
prevalence of ID of 64% and prevalence of anemia of 50% in
nonpregnant women. Because ID is the most common cause
of anemia [3, 6], an increase in ID is expected to be ac-
companied by an increase in anemia [16]. On the contrary,
depending on its etiology, ID includes both iron depletion
stages without manifestation of anemia and more severe
stages with progression to ID anemia [6]. In theory, if a given
population presents a prevalence of ID anemia over 20%, a
prevalence of some degree of ID around 50% is expected. If
the prevalence of ID anemia exceeds 40%, then almost all
population will present some degree of ID [16]. However, in
this study, we estimated the overall prevalence of anemia,
without further investigation of its underlying cause or the
concomitant presence or absence of an ID, which limits the
interpretations of the relative proportions of anemia and ID
in men and nonpregnant women [16].
Nonpregnant women in fertile age presented a signifi-
cantly increased prevalence of anemia compared to pregnant
women, being this association significant. 'is finding may
be explained by the increased prevention or surveillance of
pregnant women in Portugal, being this population group
usually targeted for additional clinical follow-up. None-
theless, despite being normally followed early during
pregnancy, iron deficiency is still underdiagnosed in Ob-
stetrics and General and Family Medicine, in which ferritin
levels are not mandatorily assessed. Furthermore, the ap-
plication of the DGS guideline for the approach, diagnosis,
and treatment of ID in adults [19] recommends pregnant
women to initiate oral iron supplementation only when their
serum ferritin concentration is <70 ng/mL. On the contrary,
the difference between the prevalence of anemia in non-
pregnant women and pregnant women should be scruti-
nized considering the pregnancy trimester. For instance, this
difference can be explained by the suppression of menstrual
blood loss during the 1st pregnancy trimester. Globally, we
found that pregnant women in the 3rd trimester, when a
significant increase in iron demand occurs, present the
highest prevalence of anemia and ferritin concentrations
<70 ng/mL, whereas pregnant women in the 1st trimester
presented a lower prevalence of these conditions. We also
found significant associations between ID and pregnancy
status, and the variation of anemia and ID prevalence along
the pregnancy trimesters was as expected. In pregnant
women, the ferritin concentration increases in the initial
gestation period in the 1st trimester and tends to progres-
sively decrease during 32 weeks to about 50% concerning the
prepregnancy levels, due to hemodilution and iron mobi-
lization [25]. 'erefore, variations in the ferritin concen-
tration are influenced by the progressive increase of iron
requirements during the 2nd and 3rd pregnancy trimesters,
induced by growth, fetal-placental and maternal tissue de-
velopment, and expansion of maternal red blood cell mass
[19, 26]. As this expansion increases during the 2nd half of
the 2nd trimester, the iron requirements reach their highest
level during the last six to eight pregnancy weeks [26].
As for the strengths of this study, we highlight its
implementation over a long period in a population-based
sample in real-life contexts, in several public locations
visited by the general population, the use of validated
analytical tests for the determination of anemia and ID
and the sample size. However, this study had some
limitations that are intrinsic to screening methodologies.
We have used a convenience sampling that depended on
participants who were willing to participate, and no
sample size calculations were performed to estimate the
representativeness of the population groups. 'us, de-
spite the considerable sample size, caution is needed
when generalizing the results of this study to the different
population groups since they have different availabilities
to participate. Furthermore, the validity of self-reported
data regarding signs or symptoms of anemia or ID and
medical history is influenced by the participants’ memory
and intellectual capacities. Finally, other factors con-
tributing to the prevalence of anemia and ID were not
analyzed [16], such as diet, clinical follow-up, comor-
bidities, and adherence to iron supplementation, mainly
in pregnant women.
5. Conclusions
We previously estimated prevalence levels of anemia or ID
above 20% in the adult Portuguese general population. In
this study, our findings provided additional evidence on the
existence of a moderate to severe public health problem,
particularly among adult women in fertile age and pregnant
women in the 3rd trimester, claiming for a preventive in-
tervention concerning a clarification in timing, duration,
and trigger cutoff.
'is screening provided a real-life picture allowing to
raise awareness among the public, healthcare professionals,
and policy-makers about the need for early and proactive
diagnosis of anemia and ID. 'e implementation of future
policies should promote further awareness and prevention
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of anemia and ID among the high-risk population groups, an
active demand for healthcare, and better treatment strate-
gies, to minimize the anemia and ID problem in Portugal.
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